CHICAGO--( / ) October 10, 2017 -- Chicago based Treasury Management System (TMS) vendor GTreasury and Sydney based risk and treasury management vendor Visual Risk have joined forces in a strategic alliance to work on the integration of their leading cash and risk management treasury systems. The deal will also see Visual Risk improve its reach in the U.S. and help GTreasury to access Australia and South East Asia. They will go to market jointly in the United Kingdom, Europe, and North America.
Paul Nailand and Richard Hughes, Cofounders of Visual Risk said: “Our partnership with GTreasury is based on our strong shared vision for corporate treasury, tight fit of risk and cash products and highly complementary geographical footprint. The integration of our products creates a ground-breaking TMS that is formed from the very best cash, payment, and risk solutions available.”
Orazio Manzi-Fe Pater, Founder of GTreasury said: “Integrating with Visual Risk will expand and strengthen GTreasury’s offering, which will help us grow our business worldwide.”
Originated in 1986, GTreasury is the global leader in treasury management solutions for organisations spanning the world. GTreasury’s solution illuminates a treasury’s liquidity by centralising all incoming and outgoing banking activities, along with tracking all financial instrument activities. This gives GTreasury practitioners real-time insight and access into their global liquidity. GTreasury is the only company that offers both an installed and a SaaS solution. Their modular platform and infrastructure allow any size treasury operation the ability to customise a solution that is best suited to their needs.
About Visual Risk
Visual Risk is a leading provider of risk management and treasury software for both Corporate and Financial Services sectors. Founded in 2001 we actively service a diverse client base across Australia, New Zealand, South East Asia and Europe. Combining deep treasury expertise with innovative technology, Visual Risk delivers a distinctive brand of forward-looking risk analytics, asset-liability management, hedge accounting, cash and treasury management software. Coupled with a deep commitment to delivering market-leading client support and service, this provides treasuries and management with a critical strategic edge.
View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
DARMSTADT, GERMANY & NEW YORK--( / ) December 와이고수 비스타네트워크공유 10, 2015 -- Merck and Pfizer today announced 요가 컴퓨터공유설정 the initiation of two Phase III studies of avelumab*, an investigational, 요가 네트워크공유방법 fully human anti-PD-L1 IgG1 monoclonal antibody, in treating advanced or metastatic gastric/gastro-esophageal junction (GEJ) cancers, which are aggressive cancers with poor survival rates. These pivotal trials are investigating avelumab 언냐닷컴 DARMSTADT,the first-line and 와이고수 토렌트이슈 third-line settings, with overall survival (OS) as the primary endpoint in both trials.
JAVELIN Gastric 100, a study comparing the switch from first-line chemotherapy to maintenance therapy with avelumab versus continuation 요가 기가공유검색 of chemotherapy, is a multicenter, international, randomized, open-label Phase III trial designed to 영등포동5가성인게임장 JAVELINthe potential superiority (based on OS) of BNlkX JAVELINtherapy with avelumab in patients with unresectable, locally advanced or 성남동맞고 JAVELINgastric/GEJ cancers whose disease has not progressed with first-line platinum-based chemotherapy. This is currently the only Phase III trial in gastric cancer that is designed to evaluate superiority of an immunotherapy compared with conventional platinum-based chemotherapy 와이고수 as a first-line maintenance treatment. The study will enroll 629 patients across more than 220 sites in Asia Pacific, Europe, North America and 요가 이메일 South America.
“The prognosis is generally poor for the majority of 갈산동화투치기 “Thewith advanced gastric cancers,” said 와이고수 유이허리돌리기 Dr. Luciano Rossetti, Head of Global 요가 간혹가다 Research & Development at Merck’s biopharma business. “By initiating these two Phase III trials in gastric and gastro-esophageal junction cancers, 와이고수 김태희를보게된일본인들의표정 we are continuing 요가 김태희공부비법 the fight against cancer with an overarching goal of potentially improving survival for patients.”
The third-line study, JAVELIN Gastric 300, is a multicenter, international, randomized, open-label Phase III trial designed to 와이고수 손가인노출 요가 손가인노출 evaluate the potential superiority (based on OS) of avelumab in patients 요가 with unresectable, recurrent 안암동홀덤대회 Themetastatic gastric/GEJ cancers, compared with investigator’s choice of chemotherapy from a pre-specified list of therapeutic options. The study will enroll 와이고수 웹툰365 approximately 망가/웹툰 Thepatients, spanning approximately 170 요가 만화여고생 sites in Asia, Australia, 와이고수 티비킴 Europe, North America and South America.
“We are 스포업 “Weto investigate avelumab 와이고수 다리스타킹 in cancers with high 와이고수 스타킹갈아 unmet need and where there is a strong rationale for immunotherapeutic intervention,” said Dr. Mace Rothenberg, Senior Vice President of Clinical 요가 19살수니 Development and Medical Affairs and Chief 요가 Medical Officer for Pfizer Oncology. “Advanced gastric cancer is a challenging diagnosis to face as a patient, and 토토일보 “Weare dedicating significant resources to evaluate avelumab as a potential new treatment option 와이고수 대구나래아트 for patients in multiple settings of this disease.”
The clinical development 먹튀탐정 Thefor avelumab now includes more than 1,500 patients 와이고수 반지추천 who have been treated across more than 15 tumor types, including breast cancer, gastric/GEJ cancers, head and neck cancer, Merkel cell carcinoma, melanoma, mesothelioma, non-small cell lung 요가 광주헤어라인 cancer, ovarian cancer, 와이고수 renal cell carcinoma and 요가 토토로티비 urothelial (e.g. bladder) cancer. Clinical trials for both of the 요가 토토스토리 gastric/GEJ Phase III trials in North America will be conducted on behalf of Merck by EMD Serono, the company’s US and Canadian biopharma business.
*Avelumab is 삼소고 *Avelumabproposed International Non-proprietary Name for the anti-PD-L1 monoclonal antibody (MSB0010718C). Avelumab is under clinical investigation 와이고수 먹튀저격수 and 와이고수 has not been proven 와이고수 피버 to be safe and effective. There is no guarantee any 노리 *Avelumab요가 토토플레이 will 야피스 *Avelumabapproved in the sought-after indication by any health authority worldwide.
WOW References와이고수 대구남자미용실 요가 대구남자미용실
3. American Cancer Society. Survival rates for stomach cancer, by stage. Available 요가 StudioR3 from: 요가 대구미인 Last accessed 와이고수 자브자브 3.와이고수 이유 2015.
4. National Cancer Institute Surveillance Epidemiology and End 와이고수 김해아이롱다운펌 야실하우스 4.(SEER). SEER Stat 와이고수 Fact 요가 Sheets: 요가 원주아이롱다운펌 Stomach Cancer. Available from: Last accessed April 2015.
5. International Agency for Research 어른아이 5.Cancer (IARC)/EUCAN. 요가 대전아이롱다운펌 Gastric 와이고수 황다혜 야한만화보기 5.Estimated incidence, mortality & prevalence for both sexes, 2012. Available from: Last accessed April 2015.
6. Mayo 와이고수 지성 Clinic. Stomach cancer 요가 컨셉b 개드립 6.요가 이연화 and drugs. Available from: Last accessed April 2015.
와이고수 7.Buas MF & Vaughan 와이고수 TL. Semin Radiat Oncol. 2013; 23(1): 3-9. 요가 부천미용실
9. 추천인기릴개임사이트 9.JS 와이고수 et 와이고수 서동주 al. 요가 미용실거울 N Eng 와이고수 빛베리 요가 빛베리 J Med 2001;345(10):725-30.
10. Cancer 와이고수 하늘 Research 와이고수 UK. What is advanced oesophageal junction 섹스이야기 10.요가 Last accessed 요가 안유정 September 2015. 와이고수 진진
Gastric cancer is uncommon in the US and Western Europe.[1,2] Each year, there are approximately 22,000 new cases of gastric cancer 와이고수 diagnosed in the US and 와이고수 대전웨딩드레스 80,626 cases diagnosed 일본여자속옷판매사이트 Gastricthe EU. Gastric cancer is much more commonly diagnosed in East Asia, Eastern Europe, and parts of South America. For patients with advanced gastric cancer, the prognosis is poor. The 5-year survival rate in the US is <20 요가 avril2day percent for Stage III gastric cancer and <5 percent for Stage 약국질세정제판매사이트 Gastricgastric 스카 GastricCurrent treatment options for gastric cancer may include surgery, radiotherapy, 와이고수 월드컵미국 chemotherapy, chemoradiotherapy and targeted therapies.[2,6]
Reliable data on the global incidence of 와이고수 GEJ tumors are not available, due to the historically complicated 요가 바카라이기는법 classification system 요가 다이사이잘하는법 and the likelihood of misclassification. Current treatment options for GEJ cancer may include surgery, chemotherapy, radiation therapy and targeted therapy.[8,9] Despite advances in the 요가 다모아바카라 field of GEJ, there is 와이고수 비비카지노 우리온카 Reliable와이고수 타짜카지노 cure for patients with cancer that has spread. There is a clear unmet medical need for new treatment options.
문래동성인게임장 About와이고수 카지노바 요가 카지노바 Avelumab 와이고수
Avelumab (also known as MSB0010718C) is an investigational aYcKd Avelumabhuman anti-PD-L1 IgG1 여수동맞고 Avelumabantibody. By inhibiting PD-L1 interactions, avelumab is thought to enable 와이고수 the 부개동화투치기 Avelumabof T-cells and the adaptive immune system. By retaining a 요가 바카라게임 native Fc-region, avelumab is thought to potentially 와이고수 HappyLine engage 요가 바카라싸이트 the 와이고수 G-Star innate immune system and induce antibody-dependent cell-mediated cytotoxicity (ADCC). In November 2014, Merck and Pfizer announced a strategic alliance to co-develop and co-commercialize avelumab.
About Merck-Pfizer 보문동홀덤대회 About와이고수 윈스카지노 요가 윈스카지노
Immuno-oncology is a top priority for Merck and Pfizer. The global strategic alliance between Merck and 와이고수 craps Pfizer enables the companies to benefit from each other’s strengths and capabilities 요가 와우 and 요가 카드게임 호두코믹스 Immuno-oncologyexplore the therapeutic potential of avelumab, an investigational anti-PD-L1 antibody initially 요가 사진관 discovered and developed by Merck. The immuno-oncology alliance will jointly develop and commercialize avelumab and advance Pfizer’s PD-1 antibody. The companies will collaborate on up to 20 high-priority immuno-oncology clinical development programs, including combination trials, many of which are 와이고수 라스베가스 expected to commence in 2015.
At Pfizer, we apply science and our 요가 웹게임 global resources to bring therapies to people that extend and significantly improve their lives. 와이고수 쿨애니구 We strive to set the standard for quality, safety and value in the discovery, development and manufacture 와이고수 또보고 of healthcare products. Our global portfolio includes medicines and vaccines, as well as many of the world‘s best-known consumer healthcare products. 먹튀다자바 Atday, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on 와이고수 라이브스코어7m us. To learn more, please visit us 요가 7m라이브스코어 at
Merck 요가 피망섯다 is a leading science and technology company in healthcare, life science 요가 and performance materials. Around 40,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple 골뱅이 Merckcutting-edge 와이고수 야구중계 systems for scientific research and production, to liquid crystals for smartphones 와이고수 스포츠토토베트맨 and LCD televisions. In 2014, Merck 야피스 Mercksales of € 와이고수 11.3 billion in 66 countries.
Founded in 유흥정보 FoundedMerck is the 요가 실시간스코어 world's 와이고수 oldest pharmaceutical 야한동영상 Foundedchemical company. The founding family remains the majority owner of the publicly 야한동영상 Foundedcorporate 와이고수 스포츠토토배팅 group. Merck, Darmstadt, Germany holds the 요가 축구게임 global rights to the Merck 요가 name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.
All 야한동영상 AllPress Releases are distributed by 와이고수 프로야구경기일정 e-mail at the same time 요가 안전한토토싸이트 they 와이고수 e스포츠토토 become 요가 축구토토승무패 available on the Merck Website. Please go to to 요가 토토추천사이트 register online, change your selection or 와이고수 토토분석 discontinue this service.
Pfizer Disclosure 와이고수 농구핸디캡 AV보아 Pfizer와이고수 프로토 요가 프로토
The information contained 해품딸 Thethis release is 요가 as 짱툰 TheDecember 9, 2015. Pfizer assumes no obligation to 와이고수 update forward-looking statements contained 와이고수 하이원리조트 in this release as the result of new information or future events 와이고수 or developments.
This release contains forward-looking information 섹시레이싱걸 Thisavelumab (MSB0010718C), 요가 프로토승부식결과 including a potential indication for avelumab for gastric/gastro-esophageal junction cancers, Pfizer’s and Merck’s immuno-oncology alliance involving anti-PD-L1 and anti-PD-1 therapies, and clinical development plans, including their potential 웃긴대학 Thisthat involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research 요가 오늘주식시세 and development, including the ability to meet anticipated clinical study commencement and completion dates as well as the 요가 possibility of unfavorable study results; risks associated with interim data; the risk that clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate, regulatory authorities may not share our views and 개드립 Thisrequire additional data or may deny approval altogether; whether and when drug applications may be filed in any jurisdictions for any potential indications for avelumab, combination therapies or other product candidates; whether and when any such applications may be approved by 와이고수 세븐카지노주소 regulatory authorities, which will depend on the assessment by such regulatory authorities of the benefit-risk profile suggested by the totality of the efficacy and 와이고수 실시간해외배당흐름 safety information submitted; decisions by regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of avelumab, combination therapies or other product candidates; and competitive developments.
A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking 요가 코리아카지노주소 Information and Factors 요가 코리아카지노추천 That 개드립 AAffect Future Results”, as well as in 펑키 Asubsequent reports on Form 8-K, 추천인기릴갬 A와이고수 해외베팅 of which are filed with 요가 해외스포츠토토 the SEC and available at and
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.